Biotech developing SV40-based gene therapies for rare and prevalent diseases.
| Date | Round | Amount |
|---|---|---|
| Dec 2021 | Funding round Leiden gene-therapy biotech Amarna Therapeutics raised EUR 5M from C4 holding, Flerie Invest and the Netherlands Enterprise Agency to advance its hemophilia B therapy. | $5.9M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.